And on this from firstmicrocapreport.com
From The Founders Of CROCS
I Give You HAIR!
This is it! The Big Mamou! Steve Beck, Founder of CROCSTM and Scott Crutchfield, the current Vice President of World Wide Operations for CROCSTM and other CROCSTM insiders have teamed up with dozens of the greatest minds, including reknowned medical doctors, to enter into what will be the hottest industry of this decade: stem cell therapy. And this company is now generating revenues with their proprietary technology of using the patient's own stem cells to the number one cosmetic procedure undergone by men: hair replacement. That's right! They are not in the position of waiting for FDA approval! They are applying their technology now!
Welcome to Biostem US Corporation (HAIR). This company will be undoubtedly be the microcap play of 2012. And to prove it, the company just now announced $5,000,000 in equity financing at a share price above Wednesday's market close. You must read this press release. It is incredible news.
This company is about to undergo a massive publicity campaign in order to inform hair replacement candidates of the stem cell procedure available to them now, through Biostem. This will automatically bring attention to the investing public and with a stock awareness program that will employ only the most reputable newsletters, I expect this stock to skyrocket this year, next year and beyond that. Follicle-ly challenged, celebrity candidates are elbowing each other out of the way in order to be selected as the celebrity patient/spokesman for this procedure, and already $2 million has been earmarked for publicity with much more to come.
And hair replacement is just the beginning. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells.
Much of the float is locked down by Rule 144 selling restrictions, so there really isn't that much stock for sale. There is no additional stock available for dilution, so the float will stay intact for the foreseeable future. That is one of the reasons that the equity funder paid higher than market price for the private placement.
A full report is being produced as we speak and will be distributed to my subscribers first, this weekend. But I urge you, to look at this now and at least take a taste. I assure you that there is very little stock available at these levels.
If you thought that my pick of LUXR at 50 cents was a great pick, that was nothing. Mark my words, HAIR is the investment of the year.
